Bempedoic Acid Cuts Venous Clot Risk by 42% in Statin-Intolerant Patients
A post hoc analysis of the CLEAR Outcomes trial finds bempedoic acid significantly reduces DVT and pulmonary embolism risk.
Summary
Bempedoic acid, a cholesterol-lowering drug used in patients who cannot tolerate statins, may also protect against dangerous blood clots. Researchers analyzed data from the CLEAR Outcomes trial — nearly 14,000 participants followed for over three years — and found that those taking bempedoic acid had 42% fewer venous thromboembolism (VTE) events compared to placebo. This included reductions in both deep vein thrombosis and pulmonary embolism. While statins and PCSK9 inhibitors were already known to reduce VTE risk, this is the first large-scale evidence suggesting bempedoic acid may offer a similar benefit. For clinicians managing statin-intolerant patients, this finding could influence prescribing decisions beyond just cholesterol control.
Detailed Summary
Venous thromboembolism — encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE) — is a serious and potentially fatal cardiovascular complication. Statins and PCSK9 inhibitors are already recognized to reduce VTE risk, but millions of patients cannot tolerate statins. For this population, understanding whether alternative lipid-lowering therapies offer similar vascular protection is clinically important.
This post hoc analysis examined data from CLEAR Outcomes, a landmark randomized, double-blind, placebo-controlled trial enrolling 13,970 statin-intolerant patients at high cardiovascular risk across 32 countries. Participants were assigned to either oral bempedoic acid (180 mg daily) or placebo and followed for a median of nearly 41 months — a robust follow-up duration for observing VTE events.
The results were striking. Only 39 VTE events occurred in the bempedoic acid group compared to 67 in the placebo group, yielding a hazard ratio of 0.58 (95% CI, 0.39–0.86; P = .006) — a 42% relative risk reduction. Both DVT and PE individually showed statistically significant reductions, with hazard ratios around 0.56 and 0.61, respectively. These findings held across a population where 2% had prior VTE history and 8.7% were already anticoagulated.
The implications are meaningful for preventive cardiology. If confirmed in prospective studies designed specifically for VTE outcomes, bempedoic acid could become a dual-purpose agent — lowering LDL cholesterol while simultaneously reducing thromboembolic risk — particularly valuable for the large segment of patients who are statin intolerant.
Important caveats apply. This was a post hoc, hypothesis-generating analysis, not a pre-specified primary endpoint. VTE events were relatively rare (106 total), limiting statistical power. The mechanism by which bempedoic acid might reduce VTE is not yet established. Full-text access was unavailable, so the summary relies on the published abstract.
Key Findings
- Bempedoic acid reduced overall VTE risk by 42% vs. placebo (HR 0.58, P = .006) over ~41 months.
- Both DVT (HR 0.56) and pulmonary embolism (HR 0.61) were individually reduced with statistical significance.
- Effect observed in a large statin-intolerant population of nearly 14,000 patients across 32 countries.
- Finding extends the VTE-protective pattern seen with statins and PCSK9 inhibitors to a new drug class.
- Bempedoic acid may serve a dual role: LDL reduction plus thromboembolic protection in high-risk patients.
Methodology
CLEAR Outcomes was a randomized, double-blind, placebo-controlled cardiovascular outcomes trial enrolling 13,970 statin-intolerant participants across 1,250 centers in 32 countries, followed for a median of 40.6 months. This VTE analysis was a post hoc secondary analysis, not a pre-specified primary endpoint. Time-to-first-event was assessed using Cox proportional hazards modeling.
Study Limitations
This is a post hoc analysis, meaning VTE was not a pre-specified primary outcome, which increases risk of false-positive findings. The absolute number of VTE events was small (106 total), limiting statistical power and subgroup analyses. The full text was not available, so this summary is based on the published abstract only; mechanistic data and full subgroup results could not be reviewed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.